She is currently focusing on new equipment for learning how cells inside our bodies interact with drugs and other chemicals. An individual cell has a large number of different receptors on its surface, and may communicate with other cells through chemical substance signals. Many pharmaceutical drugs interact with cell surface receptors to create their desired therapeutic results. Dr. Sloan is working on applying a biosensing technology created in the Bailey laboratory to study how drugs and additional chemicals interact with multiple different cell receptors concurrently.We identified novel germline mutations in DYNC1H1 and KIF5C, as well as in KIF7, KIF1A, and KIF26A. DYNC1H1 provides been implicated in polymicrogyria,21 although our four individuals with DYNC1H1 mutations experienced posterior-predominant pachygyria. DYNC1H1 forms a complex with the LIS1 protein, and the DYNC1H1 mutant phenotype is remarkably similar to the LIS1 mutant phenotype in its posterior predominance. Although we centered on identifying somatic mutations that affect the mind but are detectable at low levels in blood cells, some important somatic mutations affecting the brain look like undetectable in blood completely.23 We recently reported an AKT3 point mutation and a chromosome 1q copy-number gain associated with hemimegalencephaly, but we’re able to not detect these mutations in blood.